The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
90
Percentage of participants with improvement of AD
Time frame: Baseline through Week 16
Percentage of participants with improvement of AD
Time frame: Baseline through Week 16
Percentage of participants with TEAEs
Time frame: Baseline through Week 36
Serum concentration of TRIV-573
Time frame: Baseline through Week 36
Percentage of participants with anti-TRIV-573 antibodies
Time frame: Baseline through Week 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.